North Capital’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

North Capital’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$210	–	516
2025 Q3	$210	Buy	3 +1	+50%	+$68	﹤0.01%	652
2025 Q2	$128	Hold	2	–	–	﹤0.01%	600
2025 Q1	$127	Buy	+2	New	+$135	﹤0.01%	607

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

North Capital's PBE Position: Q4 2025 in Review

North Capital sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2025, closing a stake of 3 shares — an estimated $210 sold.

North Capital first reported a position in PBE in Q1 2025 and held it in 3 quarters. The position peaked at $210 in Q3 2025. 108 funds tracked by Wall St. Rank hold PBE as of Q4 2025.

North Capital reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2025 after selling out during the quarter.
North Capital sold 3 Invesco Biotechnology & Genome ETF shares in Q4 2025, an estimated $210.
North Capital first reported a position in Invesco Biotechnology & Genome ETF in Q1 2025 and held it in 3 quarters.
North Capital's Invesco Biotechnology & Genome ETF position peaked at $210 in Q3 2025.
108 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2025.

Based on North Capital's 13F filing for Q4 2025, filed 18 Feb 2026.